Table 2

Randomised trials with cetuximab in treatment of mCRC

			n	RR (%)	p Value	PFS	HR	p Value	OS	HR	p Value
			n	RR (%)	p Value	Median	HR	p Value	Median	HR	p Value
	First-line, ITT population
CRYSTAL	FOLFIRI		599	39	0.004	8.0	0.85	0.048	18.6	0.93	0.31
CRYSTAL	FOLFIRI+cetuximab		599	47		8.9	0.85	0.048	19.9	0.93	0.31
OPUS	FOLFOX4		168	36	0.064	7.2	0.93	0.617	NA
OPUS	FOLFOX4-cetuximab		169	46		7.2	0.93	0.617
	First-line, K-ras population
CRYSTAL	FOLFIRI	WT	176	43	0.003	8.7	0.68	0.017	21.0	0.84	0.22
	FOLFIRI-cetuximab	WT	172	59		9.9	0.68	0.017	24.9	0.84	0.22
	FOLFIRI	mut	87	40	0.46	8.1	1.07	0.75	17.7	1.03	0.85
	FOLFIRI-cetuximab	mut	105	36		7.6	1.07	0.75	17.5	1.03	0.85
OPUS	FOLFOX4	WT	73	37	0.011	7.2	0.57	0.016
	FOLFOX4-cetuximab	WT	61	61		7.7	0.57	0.016
	FOLFOX4	mut	47	49	0.10	8.6	1.83	0.019
	FOLFOX4-cetuximab	mut	52	33		5.5	1.83	0.019

ITT, intention to treat; mCRC, metastatic colorectal cancer; mut, mutated; NA, not available; OS, overall survival; PFS, progression-free survival; WT, wild type.